表皮生长因子(EGF)放射免疫分析方法建立及临床应用

Establishment and Clinical Application of an Original Method of RIA for Epidermal Growth Factor(EGF)

目的:研究表皮生长因子(epidermal growth factor,EGF)放射免疫分析方法的建立和临床应用。方法:采用人EGF对豚鼠免疫,获得高比度的抗血清,建立了体外放射免疫分析,并用来检测正常人、肝癌、糖尿病、结肠癌、肺癌、胃癌、子宫肌瘤及卵巢癌患者血清EGF浓度。结果:标准曲线范围(0.2～27)ng/ml;批内和批间(CV)分别为4.6%及8.7%;灵敏度为0.18ng/ml;回收率在95%～104%之间。分别测定正常人、肝癌、糖尿病、结肠癌、肺癌、胃癌、子宫肌瘤及卵巢癌血清EGF浓度,依次为(0.52±0.25)ng/ml,n=74;(1.29±0.58)ng/ml,n=99;(1.91±0.58)ng/ml,n=90;(1.43±0.56)ng/ml,n=90;(1.30±0.47)ng/ml,n=95;(1.25±0.58)ng/ml,n=87;(1.49±0.46)ng/ml,n=44;(1.79±0.60)ng/ml,n=54。病人血清EGF浓度与正常人经统计学处理均P<0.01,有显著性差异。结论:所建立的EGFRIA能用于临床及科研需要。

Objective To establish an original method of RIA for epidermal growth factor （EGF） for clinical use. Methods Human EGF was used to immunize guinea pig,and high titer anti-serum was obtained to establish an original method of RIA for detecting serum EGF concentration in controls and patients with liver cancer,diabetes mellitus,colon cancer,lung cancer,stomach cancer,uterinemyoma and ovary cancer. Results The standard curve range was 0.2-27ng/ml,the intra-and inter-assay CV% was 4.6% and 8.7% respectivety,the sensitivity was 0.18ng/ml,while the recovery rate was 95%~104%. The serum EGF levels in the controls were 0.52±0.25ng/ml （n=74）,patients with liver cancer 1.29±0.58ng/ml （n=99）,patients with diabetes 1.91±0.58ng/ml （n=90）,patients with colonic cancer 1.43±0.56ng/ml （n=90）,patients with lung cancer 1.30±0.47ng/ml （n=95）,patients with gastric cancer 1.25±0.58ng/ml （n=87）,patients with uterinemyoma 1.49±0.46ng/ml （n=44）,and patients with ovarian cancer 1.79±0.60ng/ml （n=54）,respectively. Serum EGF levels in each patient group were significantly （all P0.01） higher than those in controls. Conclusion The established original method of EGF RIA can be used for both clinical and research purposes.